|LE Magazine July 2001|
Page 3 of 3
1. Sztein M, Serrate S, Goldstein A. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proceedings of the National Academy of Sciences 1986; 83:6107- 6111.
2. Sztein M, Serrate S. Characterization of the immunoregulatory properties of thymosin alpha-1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. International Journal of Immunopharmacology 1989; 11:789-800.
3. Serrate S, Schulof R, Leondaridis L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, Iymphokine production, and interleukin 2 receptor expression by thymic hormones. Journal of Immunology 1987; 139:2338-2343.
4. Svedersky L, Hui A, May L, McKay P, Stebbing N. Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by Na-desacetylthymosin alpha-1. European Journal of Immunology 1982; 12:244-247.
5. Hsia J, Sarin N, OliveiJH, Goldstein AL. Aspirin and thymosin increase interleukin-2 and interferon- gamma production by human peripheral blood lymphocytes. Immunopharmacology 1989; 17:167- 173.
6. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14:409-415.
7. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha-1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. International Journal of Immunopharmacology 1990; 12:19-29.
8. Serrate S, Schulof R, Leondaridis L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, Iymphokine production, and interleukin 2 receptor expression by thymic hormones. Journal of Immunology 1987; 139:2338-2343.
9. Di Francesco P, Pica F, Gaziano R, Favalli C, Garaci E. In vivo recovery of natural killer cell activity by the association of thymosin alpha-1 and cytokines during cocaine administation. Medical Science Research 1994; 22:41-42.
10. Favalli C, Mastino A, Jezzi T,Grelli S, Goldstein AL, Garaci E. Synergistic effect of thymosin alpha-1 and alpha beta-interferon on NK activity in tumor-bearing mice. International Journal of Immunopharmacology 1989; 11:443-450.
11. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14:409-415.
12. Salvati F, Rasi G, Portalone L, Antilli A, Garaci E. Combined treatment with thymosin alpha-1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial. Anticancer Research 1996; 16:1001-1004.
13. Moody TW, Fagarasan M, Zia F, Cesnjaj M, Goldstein AL. Thymosin alpha-1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Research 1993; 53: 5214-5218.
14. Moody T, Badamchian M, GoldsteiftA. Thymosin alpha-1 prevents lung carcinogenesis. FASEB Journal 1998; 12:A1457.
15. Hunt C, Dominitz I, Philips Bute B, Waters B, Blasi U, Williams D. Effect of interferon alpha treatment of chronic hepatitis C on health-related quality of life. Digestive Diseases and Sciences 1997; 42:2482-2486.
16. Lau G, Yuen S, KwokA, Lai S, Lim W, Lam S. Six-months follow-up on a 26 week trial of thymosin alpha-1 plus famciclovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B. Gastroenterology 1999; 116.
17. Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha-1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27:1128-35.
18. Rasi G, DiVirgilio D, Mutchinick MG, et al. Combination thymosin alpha-1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996; 39:670-683.
19. Moscarella S, Buzzelli G, Monti M, et al. Treatment with interferon-alpha and thymosin alpha-1 of naive patients affected by chronic hepatitis C. 4th International Meeting on Hepatitis C Virus and Related Viruses. Kyoto, Japan, 1997.
20. Bonkovsky H. Therapy of hepatitis C: other options. Hepatology 1997; 26:1435-1515.
21. Garaci E, Rocchi G, Perroni L, et al. Combined therapy with zidovudine-thymosin alpha-1 alpha interferon in the treatment of HIV-infected patients. Second International Symposium on Combination Therapies, Sicily, Italy, 1992.
22. de Weck A, Kristensen F, Joncourt F, Bettens F, Walker C, Wang Y. Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions. Springer Seminars in Oncology 1984; 7:273-289.
23. Makinodan T, Peterson W. Relative antibody-forming capacity of spleen cells as a function of age. Proceedings of the National Academy of Sciences 1962; 48:234-238.
24. Wade AW, Szewczuk MR. Aging, idiotype repertoire shifts, and compartmentalization of the mucosal-associated lymphoid system. Adv lmmunol 1984; 36:143-88.
25. Ershler W, Moore A, Socinski M. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. Journal of Clinical Immunology 1984; 4:445- 454.
26. Ershler W, Moore A, Hacker M, Ninomiya J, Naylor P, Goldstein A. Specific antibody synthesis in vitro II. Age-associated thymosin enhancement of antitetanus antibody synthesis. Immunopharmacology 1984; 8:69- 77.
27. Dammin G, Couch N, Murray J. Prolonged survival of skin homografts in uremic patients. Second Tissue Homotransplantation Conference, New York, 1957. Annals of the New York Academy of Sciences.
28. Lawrence HS. Uremia: nature’s immunosuppressive device [editorial]. Ann Intern Med 1965; 62:166- 70.
29. Sanders CV, Jr., Luby JP, Sanford JP, Hull AR. Suppression of interferon response in lymphocytes from patients with uremia. J Lab Clin Med 1971; 77:768-76.
30. Bramwell SP, Tsakiris Dl, Briggs JD, et al. Dinitrochlorobenzene skin testing predicts response to hepatitis B vaccine in dialysis patients. Lancet 1985; 1:1412-5.
31. Revie D, Shen S, Ordonez J, et al. T-cell subsets and status of hepatitis B surface antigen and antibody in end-stage renal disease patients. Kidney International 1985; 27: 150.
32. Lee R. Neoplasms and other masses. Diagnostoc Liver Pathology. Vol. 1. St. Lquis: Mosby, 1994: 487-499.
33. Carr B, Flickinger I, Lotze M.Hepatobiliary Cancers. In: deVita Ir V, Hellman S, Rosenberg S, eds. deVita. Cancer: Principles and Practice of Oncology. Vol. 1. Philadelphia: Lippincott-Raven Publishers, 1997:1088-1109.
34. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 1998; 45:209-15.
35. Boring CC, Squires TS, Tong T. Cancer statistics, 1992 [published erratum appears in CA Cancer J Clin 1992 Mar-Apr;42(2): 127-8]. CA Cancer I Clin 1992; 42:19-38.
36. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer I Clin 1993; 43:7-26.
37. Schulof RS, Lloyd MI, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin alpha-1 in patients with lung cancel. Journal of Biological Response Modifiers 1985; 4:147-158.
38. Lopez M, Di Lauro L, Vici P, et al. Biological agents and chemotherapy in the treatment of solid tumors. Third International Symposium on Combination Therapies, Houston, Texas, 1993. Institute for Advanced Studies in Immunology & Aging.
39. Garbe C, Kreuser E. Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Seminars in Oncology 1992; 19:63-69.
40. Falkson C, Falkson G. 1mproved results with the addition of reconbinant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. Proceedings of the American Association of Cancer Research 1990; 31:Al185.
41. Houghton A, Legha S, Bajorin D. Chemotherapy for metastatic melanoma. In: Balch C, Houghton A, Sober A, eds. Cutaneous Melanoma. Philadelphia: Lippincott, 1992:498-508.
42. Favalli C. Combination therapy in malignant melanoma. Third International Symposium on Combination Therapies, Houston, Texas, 1993. Institute for Advanced Studies in Irnmunology & Aging.
43. Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin alpha-1 and low-dose interferon alpha after dacarbazine in advanced melanoma. Melanoma Research 2000: in press.
Back to the Magazine Forum